B+
Bull case
30%
Probability
Target price
$88.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
LIVN
LivaNovaCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The strongest post-print read is straightforward: core franchises accelerated, guidance moved higher, and the company now has both a fresh FDA approval and a visible OSA launch roadmap. Secondary market-data sources indicated Q1 results were above pre-report consensus on both revenue and adjusted EPS, which supports a higher forward setup if estimate revisions follow.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Neuromodulation growth remained solid, but adjusted segment margin in that segment eased year over year, showing that not all operating leverage is flowing through cleanly [#8-K-2026-05-06].
Momentum
48
Value
56
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $81.20 · Bull $88.00 · Bear $60.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $92.10
Why
Momentum48 · Δ7d -0.0
Value56 · Δ7d -0.3
Sentiment46 · Δ7d -3.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • Neuromodulation growth remained solid, but adjusted segment margin in that segment eased year over year, showing that not all operating leverage is flowing through cleanly [#8-K-2026-05-06].
- • OSA is still in an early launch phase; the earnings slides show a limited market release in H2 2026 and full market release in H1 2027, so commercialization and reimbursement execution remain open risks [#8-K-2026-05-06].
- • This is still a monitoring-style medtech thesis rather than a clean breakout.
Catalyst clock
2026-05-06
Q1 beat-and-raise resets near-term expectations
Lead driver: Value · See fundamentals
Momentum
48
8% active weight
Current posture
7d trendImproving
Δ7d
-0.0
Δ21d
-2.2
Value
56
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.7
Sentiment
46
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
-17.6
Why this grade
Composite grade C. Momentum 47.7 / Value 55.8 / Sentiment 45.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$81.20
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$4.46B
Beta
0.97
Shares Out
55.09M
P/E (TTM) · Derived
-18.2
P/S (TTM)
2.56
P/FCF (TTM)
18.04
Rev YoY
+10.8%
EPS YoY
+288.6%
Gross Margin
+68.2%
Op Margin
+15.0%
Net Debt
-$201.78M
Current Ratio
1.45
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data